Global Allergy Immunotherapies Market is estimated to grow at 10.7% CAGR till 2025

Allergy immunotherapy, also called as hypo-sensitization or desensitization, is a medical therapy targeted to counteract allergies. There is a subtle increment in the risk of allergy, and pharmacotherapy is not enough to control the rate of occurrence alone. Allergy immunotherapeutic treatment boosts immunological tolerance and can alter the course of the disease. It is estimated that allergies are the sixth leading cause of chronic illness in North America according to the American College of Allergy, Asthma & Immunology. Over 50 million Americans face various types of allergies annually as per a study conducted by Centers for Disease Control and Prevention (CDC).

There are several factors that are driving the Global Allergy Immunotherapies Market. The subcutaneous immunotherapy (SCIT) is mostly utilized and efficient kind of allergy immunotherapy. The SCIT treatment alters the immune system, thereby preventing the development of new allergies and asthma. Allergy tablets are a type of SLIT that treats certain allergies. These allergy tablets decrease the symptoms by helping the body build resistance to allergen effects. However, pharmaceutical tablets can only treat only a single type of allergen and cannot protect from asthma and new allergy developments. The US Food and Drug administration (FDA) authorized SLIT tablets to treat ragweed and grass pollen allergies in 2014.

Research Cosmos very recently published a research report on Global Allergy Immunotherapies Market, the report estimated the market to reach USD XX Billion by 2025.

Browse more details of the report @ https://www.researchcosmos.com/reports/allergy-immunotherapies-market-research-report-global-industry-analysis-and-forecast-2018-to-2023/1296763373

Based on geography the Global Allergy Immunotherapies Market primarily segmented into Europe, North America, Latin America, Middle East & Africa and North America. North America and Europe regions are estimated to be claiming major part of the global share, followed by Asia Pacific region. The Asia Pacific region is predicted to be growing faster with highest pace of CAGR during forecasted years. China and Japan are predicted to be dominating markets in the region.

DBV Technologies, Circassia, Aimmune Therapeutics, Anergis, Biomay AG, HAL Allergy Group, Merck KGaA (Allergopharma), Allergy Therapeutics, ALK-Abello A/S, and Greer are the prominent players in the Global Allergy Immunotherapies Market.

The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.

The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.

What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.

Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We’re associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.

4390 U.S 1, Suite 211,
www.researchcosmos.com

This release was published on openPR.